MedTrace Logo

MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)

NCT04004559 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2020-06-29

No results posted yet for this study

Summary

This study is aimed to illustrate whether Radiomics combining multiparametric MRI before and after neoadjuvant chemotherapy (NACT) with clinical data is a good way to predict axillary lymph node metastasis and prognosis in invasive-breast-cancer.

Conditions

Interventions

OTHER

No interventions

As this is a patient registry, there are no interventions.

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • Tungwah Hospital of Sun Yat-Sen University

    collaborator UNKNOWN

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Herui Yao, PhD · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  • Chuanmiao Xie, PhD · Sun Yat-sen University

  • Haotian Lin, PhD · Zhongshan Ophthalmic Center, Sun Yat-sen University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-28
Primary Completion
2020-10-30
Completion
2025-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04004559 on ClinicalTrials.gov